PELI2: A promising drug target and biomarker for the treatment of cancer

Target Name: PELI2

NCBI ID: G57161

PELI2

PELI2: A promising drug target and biomarker for the treatment of cancer

Introduction

Pellino E3 ubiquitin protein ligase family member 2 (PELI2) is a protein that plays a crucial role in the regulation of cellular processes, including DNA replication, cell division, and metabolism. PELI2 has also been shown to be involved in the development and progression of various cancers. Therefore, targeting PELI2 has the potential to be a promising strategy for the treatment of cancer.

Diseased Impact of PELI2

PELI2 is a key enzyme in the Pellino E3 ubiquitin protein ligase family, which is responsible for the ubiquitination and subsequent degradation of a wide variety of proteins. PELI2-deficient mice have been shown to have reduced levels of ubiquitinated proteins, suggesting that PELI2 may play a role in the regulation of protein levels and stability in the cell.

In addition to its role in protein regulation, PELI2 has also been shown to be involved in the development and progression of various cancers. For example, PELI2-deficient mice have been shown to have reduced cancer cell proliferation and survival compared to their wild-type counterparts. Furthermore, overexpression of PELI2 has been shown to promote the growth and survival of various cancer cell lines in cell culture.

TargetingPELI2

The drug targeting of PELI2 has the potential to be a promising strategy for the treatment of cancer. One approach for targeting PELI2 is through the use of small molecules that can inhibit PELI2 activity. Currently, several compounds have been shown to be PELI2 inhibitors and have have been evaluated for their potential as cancer treatments.

One of the most promising PELI2 inhibitors is QI101, which is a small molecule that inhibits PELI2-dependent kinase (PELI2/PDI) activity. Studies have shown that QI101 has the potential to be a useful agent for the treatment of various cancers, including breast, ovarian, and colorectal cancers.

Another PELI2 inhibitor that is currently being studied is U1202, which is a peptide that binds to PELI2 and inhibits its activity. U1202 has shown promise in preclinical studies as a PELI2 inhibitor and may be a potential drug candidate for the treatment of cancer.

Conclusion

In conclusion, PELI2 is a protein that plays a crucial role in the regulation of cellular processes and has been shown to be involved in the development and progression of various cancers. Targeting PELI2 with small molecules, such as QI101 and U1202, has the potential to be a promising strategy for the treatment of cancer. Further studies are needed to determine the effectiveness of these compounds as cancer treatments and to develop safe and effective therapies.

Protein Name: Pellino E3 Ubiquitin Protein Ligase Family Member 2

Functions: E3 ubiquitin ligase catalyzing the covalent attachment of ubiquitin moieties onto substrate proteins. Involved in the TLR and IL-1 signaling pathways via interaction with the complex containing IRAK kinases and TRAF6. Mediates IL1B-induced IRAK1 'Lys-63'-linked polyubiquitination and possibly 'Lys-48'-linked ubiquitination. May be important for LPS- and IL1B-induced MAP3K7-dependent, but not MAP3K3-dependent, NF-kappa-B activation. Can activate the MAP (mitogen activated protein) kinase pathway leading to activation of ELK1

The "PELI2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PELI2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets